Gentherapie Archives | Cogem

Advice Reassessment of the threshold values for the presence of free lentiviral and retroviral vector particles in clinical trials with ex vivo transduced cells

20.05.2025

CGM/250520-01

Advisory reports
Joint open letter COGEM and ZKBS on the ERA of new vaccine developments based on samRNAs and VRPs

14.05.2025

CGM/250514-01

Policy reports
The Value of Gene Therapy. A study of the growth, cost and accessibility of gene therapy products

18.10.2024

CGM/240624-01

Policy reports
Generic environmental risk assessment of gene therapies that use GM cells containing free lentiviral particles

07.05.2020

CGM/200507-01

Advisory reports
Generic environmental risk assessment of clinical trials with AAV vectors

11.02.2020

CGM/190905-01

Advisory reports
Immunotherapy with genetically modified T cells: unintended exposure and potential risks

27.02.2019

CGM/190227-01

Policy reports
Generic advice on containment levels for replication-deficient adenoviral vector systems

16.03.2018

CGM/180316-01

Advisory reports
Research report Assessment of preclinical gene therapy studies worldwide

04.09.2015

CGM 2015-03

Research reports
Replication-competent non-human viruses for use in clinical gene therapy: an inventory study

12.01.2011

CGM 2010-10

Research reports
International medical tourism from the Netherlands for gene therapy

29.11.2010

CGM 2010-07

Research reports
Gene therapy with naked DNA: Potential steps towards deregulation

26.10.2010

CGM 2010-06

Research reports